Tanya Wiese, DO
Pulmonary Disease · Louisville, KYNPI 1992737886
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $845 and has fallen 88.7% since, to $95 in 2021. That places this record below the midpoint for pulmonary disease clinicians in KY, where the typical reported total is $4,124.
Across 60 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$233
- Boehringer Ingelheim$219
- Sunovion Pharmaceuticals Inc.$141
- Grifols USA, LLC$117
- Pulmonx Corporation$114
- Insmed, Inc.$97
- plus $236 from 10 others
Across 10 payments — averaging $7373.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$74K
What the payments were for
- Food & beverage$1,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $233 |
| Boehringer Ingelheim | 8 | $219 |
| Sunovion Pharmaceuticals Inc. | 10 | $141 |
| Grifols USA, LLC | 8 | $117 |
| Pulmonx Corporation | 2 | $114 |
| Insmed, Inc. | 7 | $97 |
| Philips North America LLC | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $34 |
| Mylan Specialty L.p. | 2 | $32 |
| Genentech USA, Inc. | 2 | $32 |
| Phadia US Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Pfizer | 1 | $13 |
| AstraZeneca | 1 | $12 |
How this compares
$1,156 in reported general payments places this provider in the 20th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.